Modified bone drug kills malaria parasite in mice
L. Brian Stauffer
The researchers found the drug by screening a library of about 1,000 compounds used in previous efforts to target an important biochemical pathway (called isoprenoid biosynthesis) in cancer and in disease-causing organisms. The new drug lead, BPH-703, inhibits a key enzyme in isoprenoid biosynthesis that enables the malaria parasite to sustain itself and defend itself from the host immune system. The drug has little effect on the same chemical pathway in human or mouse cells, said University of Illinois chemistry professor Eric Oldfield, who led the study.
The lead compounds are chemically modified forms of the osteoporosis drugs Actonel (Risedronate) and Zometa (Zoledronate), Oldfield said. Risedronate and Zoledronate potently block isoprenoid biosynthesis, but are unable to get across the membrane of red blood cells to get to the parasite. The modified forms include a long lipid tail that helps them pass through the lipid-rich membrane of red blood cells, and also enhances the drug's ability to bind to the target enzyme, geranylgeranyl diphosphate synthase (GGPPS), he said.
"We found that compounds that were really active had a very long hydrocarbon chain," Oldfield said. "These compounds can cross the cell membrane and work at very low concentrations."
"We are the first to show that the enzyme GGPPS is a valid target for malaria," said study co-author Yonghui Zhang, a research scientist in Oldfield's lab and inventor of the lead compound, BPH-703. "Our work gives a new direction to find new antimalarial drugs."
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.